ATXN7

Across TCGA pan-cancer cohorts, ATXN7 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ATXN7 data layer compared with 25 for mass-spec protein and 12 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ATXN7 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ATXN7 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, LSCC, and PDAC are the cancer types where ATXN7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.935	0.799	.009	10	view →
LSCC	OS	Median	All	1.000	0.939	.014	3	view →
PDAC	OS	Quartile	All	0.202	0.527	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ATXN7–HNSC (OS)

Open the HNSC breakdown →